News

A new type of CAR T-cell therapy elicits a more controlled immune response to cancer in mice, effectively killing cancer cells with fewer side effects.

PVEK, a CD123-targeting antibody-drug conjugate, demonstrated strong response rates in two studies. Combined with VEN/AZA, it produced high remissions in CD123-positive AML and as monotherapy, it delivered high responses in high-risk BPDCN patients.

A world-first base-edited CAR-T therapy has helped previously untreatable for T-cell acute lymphoblastic leukemia patients achieve remission, with 82% responding and many now disease-free.

Cold Spring Harbor scientists traced the CLE gene family across 1,000 plant species using AI to predict hidden redundant genes that mask key traits. CRISPR tests in tomatoes confirmed the forecasts.

A Karolinska Institutet study of nearly 400 patients shows that a lower dose of ipilimumab in combination immunotherapy for advanced melanoma leads to better tumor response, longer survival and fewer side effects compared to the traditional regimen.

Biotech and pharma greenhouse gas emissions are falling – but is current progress fast enough? Discover My Green Lab’s Impact Report.

KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, reducing dangerous spikes linked to side effects and enabling personalized, safer mRNA therapies.

When exposed to green light, the protein AR3 increases alkalinity in cells, disrupting cellular functions and causing apoptosis.

Researchers identified a bacterial enzyme that enables Streptococcus pneumoniae to invade heart cells and cause damage, explaining why some pneumonia patients suffer cardiac complications.

Researchers have developed a new antibody that could help to destroy hard-to-treat tumours more effectively, with fewer side effects than some current therapies.